157 related articles for article (PubMed ID: 26038841)
1. Prevalence and clinical significance of abnormal serum kappa/lambda light chain ratio in patients with chronic kidney disease.
Niewmierzycka A; Kurman M; Leśniak M; Winiarska A; Pawłowska A
Pol Arch Med Wewn; 2015; 125(7-8):532-7. PubMed ID: 26038841
[TBL] [Abstract][Full Text] [Related]
2. Diagnostic reference range of κ/λ free light chain ratio to screen for Bence Jones proteinuria is not significantly influenced by GFR.
Schmidt-Hieltjes Y; Elshof C; Roovers L; Ruinemans-Koerts J
Eur J Haematol; 2016 May; 96(5):527-31. PubMed ID: 26172558
[TBL] [Abstract][Full Text] [Related]
3. The renal range of the κ/λ sFLC ratio: best strategy to evaluate multiple myeloma in patients with chronic kidney disease.
Molina-Andújar A; Robles P; Cibeira MT; Montagud-Marrahi E; Guillen E; Xipell M; Blasco M; Poch E; Rosiñol L; Bladé J; Quintana LF
BMC Nephrol; 2020 Mar; 21(1):111. PubMed ID: 32234026
[TBL] [Abstract][Full Text] [Related]
4. Glomerular filtration rate as a determinant of free light chains in renal transplantation.
Bargnoux AS; Simon N; Garrigue V; Dupuy AM; Badiou S; Mourad G; Cristol JP
Clin Biochem; 2013 Nov; 46(16-17):1764-6. PubMed ID: 24028899
[TBL] [Abstract][Full Text] [Related]
5. The association of serum-free light-chain levels with markers of renal function.
Erdem BK; Davran F; Yilmaz VT; Çetinkaya R; Akbas H
Ren Fail; 2015 Jul; 37(6):1057-60. PubMed ID: 26056734
[TBL] [Abstract][Full Text] [Related]
6. Hemodiafiltration improves free light chain removal and normalizes κ/λ ratio in hemodialysis patients.
Bourguignon C; Chenine L; Bargnoux AS; Leray-Moragues H; Canaud B; Cristol JP; Morena M
J Nephrol; 2016 Apr; 29(2):251-257. PubMed ID: 26022721
[TBL] [Abstract][Full Text] [Related]
7. Serum Free Light Chain Assay: Shift Toward a Higher κ/λ Ratio.
Rindlisbacher B; Schild C; Egger F; Bacher VU; Pabst T; Leichtle A; Andres M; Sédille-Mostafaie N
J Appl Lab Med; 2020 Jan; 5(1):114-125. PubMed ID: 32445339
[TBL] [Abstract][Full Text] [Related]
8. Serum Free Light Chain Assay and κ/λ Ratio Performance in Patients Without Monoclonal Gammopathies: High False-Positive Rate.
Singh G
Am J Clin Pathol; 2016 Aug; 146(2):207-14. PubMed ID: 27473738
[TBL] [Abstract][Full Text] [Related]
9. Quantitative assessment of serum and urinary polyclonal free light chains in patients with chronic kidney disease.
Hutchison CA; Harding S; Hewins P; Mead GP; Townsend J; Bradwell AR; Cockwell P
Clin J Am Soc Nephrol; 2008 Nov; 3(6):1684-90. PubMed ID: 18945993
[TBL] [Abstract][Full Text] [Related]
10. Association between free light chain levels, and disease progression and mortality in chronic kidney disease.
Desjardins L; Liabeuf S; Lenglet A; Lemke HD; Vanholder R; Choukroun G; Massy ZA;
Toxins (Basel); 2013 Nov; 5(11):2058-73. PubMed ID: 24217396
[TBL] [Abstract][Full Text] [Related]
11. In-house age-specific reference ranges for free light chains measured on the SPAPlus® analyser.
Campbell L; Simpson D; Shields A; Ferry B; Ramasamy K; Sadler R
Ann Clin Biochem; 2020 Mar; 57(2):138-143. PubMed ID: 31852213
[No Abstract] [Full Text] [Related]
12. Comparison of Freelite™ and N Latex serum free light chain assays in subjects with end stage kidney disease on haemodialysis.
Kennard A; Hawley C; Tate J; Klingberg S; Pretorius C; Hutchison C; Mollee P
Clin Chem Lab Med; 2016 Jun; 54(6):1045-52. PubMed ID: 26684350
[TBL] [Abstract][Full Text] [Related]
13. POEMS Syndrome with IgG-λ/IgA-κ Biclonal Gammopathy and Abnormal Serum Free Light Chain Ratio: a Case Report.
Ham JY; Suh JS; Lee WK; Song KE
Ann Clin Lab Sci; 2015; 45(6):702-6. PubMed ID: 26663802
[TBL] [Abstract][Full Text] [Related]
14. Unravelling the immunopathological mechanisms of heavy chain deposition disease with implications for clinical management.
Bridoux F; Javaugue V; Bender S; Leroy F; Aucouturier P; Debiais-Delpech C; Goujon JM; Quellard N; Bonaud A; Clavel M; Trouillas P; Di Meo F; Gombert JM; Fermand JP; Jaccard A; Cogné M; Touchard G; Sirac C
Kidney Int; 2017 Feb; 91(2):423-434. PubMed ID: 27773425
[TBL] [Abstract][Full Text] [Related]
15. Serum reference intervals and diagnostic ranges for free kappa and free lambda immunoglobulin light chains: relative sensitivity for detection of monoclonal light chains.
Katzmann JA; Clark RJ; Abraham RS; Bryant S; Lymp JF; Bradwell AR; Kyle RA
Clin Chem; 2002 Sep; 48(9):1437-44. PubMed ID: 12194920
[TBL] [Abstract][Full Text] [Related]
16. Hemodiafiltration with ultrafiltrate regeneration reduces free light chains without albumin loss in multiple myeloma patients.
Pendón-Ruiz de Mier MV; Ojeda R; Álvarez-Lara MA; Navas A; Alonso C; Caballero-Villarraso J; Aljama P; Álvarez MA; Soriano S; Rodríguez M; Martín-Malo A
BMC Nephrol; 2020 Jun; 21(1):227. PubMed ID: 32539688
[TBL] [Abstract][Full Text] [Related]
17. [Analysis of monoclonal protein in 72 cases of multiple myeloma].
Yang JJ; Zhang GS; Chen XR
Hunan Yi Ke Da Xue Xue Bao; 2001 Apr; 26(2):152-4. PubMed ID: 12536652
[TBL] [Abstract][Full Text] [Related]
18. [Analysis of the relationship of heavy/light chain pairs of immunoglobulin (Hevylite) to the results of gel electrophoresis and nefelometric examination of serum proteins at the time of multiple myeloma diagnosis].
Ščudla V; Lochman P; Pika T; Zapletalová J; Minařík J; Bačovský J
Cas Lek Cesk; 2015; 154(6):292-302. PubMed ID: 26750626
[TBL] [Abstract][Full Text] [Related]
19. Light Chain Deposition Disease Associated With Multiple Myeloma Developing in Late Pregnancy.
Kim MJ; Kim JH; Kim IY; Lee SB; Park IS; Han MY; Rhee H; Song SH; Seong EY; Kwak IS; Lee DW
Iran J Kidney Dis; 2018 Mar; 12(2):132-134. PubMed ID: 29507277
[TBL] [Abstract][Full Text] [Related]
20. The predictive power of serum kappa/lambda ratios for discrimination between monoclonal gammopathy of undetermined significance and multiple myeloma.
Bergón E; Miravalles E; Bergón E; Miranda I; Bergón M
Clin Chem Lab Med; 2005; 43(1):32-7. PubMed ID: 15653439
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
